Abstract:Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as an attractive therapeutic target for cardiovascular disease. Monoclonal antibodies (mAbs) that bind PCSK9 and prevent PCSK9:low-density lipoprotein receptor complex formation reduce serum low-density lipoprotein-cholesterol (LDL-C) in vivo. PCSK9-mediated lysosomal degradation of bound mAb, however, dramatically reduces mAb exposure and limits duration of effect. Administration of high-affinity mAb1:PCSK9 complex (1:2) to mice resulted in significantly lower mAb1 exposure compared with mAb1 dosed alone in normal mice or in PCSK9 knockout mice lacking antigen. To identify mAb-binding characteristics that minimize lysosomal disposition, the pharmacokinetic behavior of four mAbs representing a diverse range of PCSK9-binding affinities at neutral (serum) and acidic (endosomal) pH was evaluated in cynomolgus monkeys. Results revealed an inverse correlation between affinity and both mAb exposure and duration of LDL-C lowering. High-affinity mAb1 exhibited the lowest exposure and shortest duration of action (6 days), whereas mAb2 displayed prolonged exposure and LDL-C reduction (51 days) as a consequence of lower affinity and pH-sensitive PCSK9 binding. mAbs with shorter endosomal PCSK9:mAb complex dissociation half-lives (<20 seconds) produced optimal exposure-response profiles. Interestingly, incorporation of previously reported Fc-region amino acid substitutions or novel loop-insertion peptides that enhance in vitro neonatal Fc receptor binding, led to only modest pharmacokinetic improvements for mAbs with pH-dependent PCSK9 binding, with only limited augmentation of pharmacodynamic activity relative to native mAbs. A pivotal role for PCSK9 in mAb clearance was demonstrated, more broadly suggesting that therapeutic mAb-binding characteristics require optimization based on target pharmacology.

Development of an indirect ELISA for determination of antigen-binding activity of monoclonal antibody against proprotein convertase subtilisin/kexin type 9

Preparation of Monoclonal Antibody Against Chloramphenicol and Establishment of Direct Competitive ELISA for Determination of Chloramphenicol

Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3

Ultrasensitive Homogeneous Detection of PCSK9 and Efficacy Monitoring of the PCSK9 Inhibitor Based on Proximity Hybridization-Dependent Chemiluminescence Imaging Immunoassay.

Development of a Monoclonal Antibody-Based Direct Competitive Enzyme-Linked Immunosorbent Assay for a New Β-Adrenergic Agonist Phenylethanolamine A

Development of An Enzyme Linked Immunosorbant Assay(ELISA) for Detection of Coplanar Polychlorinated Biphenyls(PCBs)

[Development and Application of CK-MB Specific Monoclonal Antibodies].

Identification of Dominant Conformational Epitopes from the Whole Structure of the Proprotein Convertase Subtilisin/kexin Type 9.

Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Quantification of a Recombinant Humanized Anti-Il-4rα Monoclonal Antibody CM310 in Serum and Its Application to Pharmacokinetic Study in Sprague-Dawley Rats.

[Establishment and Optimization of an ELISA for Affinity Detection of Single-Chain Antibodies to EGFRvIII].

Development of an indirect competitive ELISA based on monoclonal antibodies for detection of ractopamine

Preparation of monoclonal antibody against human tissue kallikrein and development of an ELISA kit

Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia

Development of an Direct Competitive ELISA for Screening of Chloramphenicol Residue and Preliminary Application

Establishment of Antibody Indirect ELISA and its Initial Application

Anti-PCSK9 Antibody Pharmacokinetics and Low-Density Lipoprotein-Cholesterol Pharmacodynamics in Nonhuman Primates Are Antigen Affinity–Dependent and Exhibit Limited Sensitivity to Neonatal Fc Receptor–Binding Enhancement

Development of a Monoclonal-Based Ic-Elisa for the Determination of Kitasamycin in Animal Tissues and Simulation Studying Its Molecular Recognition Mechanism.

[Preparation and Characterization of the Monoclonal Antibodies Against Human CA19-9 and Establishment of a Sandwich CLIA System].

[Preparation and Characterization of Monoclonal Antibodies Against Human CA50 and Establishment of Chemiluminescence Immunoassay System].

A Sensitive and Rapid Chemiluminescence Immunoassay for Point-of-care Testing (POCT) of Copeptin in Serum Based on High-Affinity Monoclonal Antibodies Via Cytokine-Assisted Immunization

A Convenient Enzyme Linked Immunosorbent Assay Method for Antibody Affinity Qualitative Comparison